CANI, ALICE
 Distribuzione geografica
Continente #
NA - Nord America 444
EU - Europa 295
AS - Asia 73
AF - Africa 1
Totale 813
Nazione #
US - Stati Uniti d'America 444
PL - Polonia 190
CN - Cina 47
IT - Italia 37
UA - Ucraina 21
TR - Turchia 14
GB - Regno Unito 13
DE - Germania 12
BE - Belgio 6
VN - Vietnam 6
FI - Finlandia 5
SE - Svezia 5
HK - Hong Kong 3
HU - Ungheria 2
IN - India 2
RO - Romania 2
BG - Bulgaria 1
EG - Egitto 1
FR - Francia 1
JP - Giappone 1
Totale 813
Città #
Warsaw 190
Fairfield 62
Houston 50
Chandler 47
Woodbridge 45
Ann Arbor 38
Ashburn 32
Jacksonville 25
Seattle 24
Wilmington 21
Cambridge 18
Ferrara 13
Nanjing 9
Beijing 7
Boardman 7
Izmir 7
Princeton 7
Shanghai 7
Brussels 6
Dong Ket 6
Milan 5
Nanchang 5
Cagliari 4
Dearborn 4
London 4
New York 4
Sant'elena 4
Hebei 3
Shenyang 3
Addison 2
Bremen 2
Changsha 2
Focsani 2
Győr 2
Harringay 2
Hong Kong 2
Jinan 2
Roncoferraro 2
Zhengzhou 2
Ankara 1
Bhavnagar 1
Bologna 1
Central District 1
Chengdu 1
Des Moines 1
El Mahalla El Kubra 1
Harbin 1
Helsinki 1
Lanzhou 1
Los Angeles 1
Norwalk 1
Potomac 1
Pune 1
Quzhou 1
Redmond 1
Redwood City 1
San Diego 1
Tappahannock 1
Tianjin 1
Varna 1
Wuhan 1
Xian 1
Yellow Springs 1
Totale 701
Nome #
Targeting the PI3K/Akt/mTOR signaling pathway as a new therapeutic strategy for personalized treatments in acute lymphoblastic leukemia 183
Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia 144
miR-199a-3p Modulates MTOR and PAK4 Pathways and Inhibits Tumor Growth in a Hepatocellular Carcinoma Transgenic Mouse Model 140
Epstein-Barr virus-specific antibody response in cerebrospinal fluid and serum of patients with multiple sclerosis 129
Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential. 125
Quantification of CSF and serum levels and intrathecal synthesis of anti-EBV antibodies in patients with multiple sclerosis and with other neurological disorders. 75
Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation. 16
Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia. 13
The AKT Inhibitor MK-2206 is Cytotoxic in Hepatocarcinoma Cells Displaying Hyperphosphorylated AKT-1 and Synergizes with Conventional Chemotherapy 9
Totale 834
Categoria #
all - tutte 3.006
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.006


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201950 0 0 0 0 0 0 0 0 0 0 22 28
2019/2020210 25 10 10 24 17 22 16 23 14 22 13 14
2020/2021194 14 21 10 13 17 18 14 17 10 37 13 10
2021/202275 1 16 10 0 4 5 3 3 3 6 9 15
2022/2023102 10 7 9 14 15 15 6 7 9 1 7 2
2023/202458 3 5 3 0 5 12 5 16 2 1 6 0
Totale 834